Author

T. M. Aljarba

h-index 10 View on Semantic Scholar

We have 4 of 56 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Phytochemical Profile and Pharmacological Potentials of Solanum dubium (Fresen.)

Solanum dubium Fresen. is a species of the Solanaceae family. It is an indigenous wild plant of Sudan and other East African countries. The aim of this review is to explore and analyze its phytochemical constituents and pharmacological activities. The review followed the Preferred Reporting Items for Systematic reviews...

Wadah Osman, Mohamed Mirghani, Aisha Mohamed Kosar et al. · Natural Resources for Human... · 0 citations

Review Aug 2026

Purine-centred fused, conformationally constrained, and ring-expanded analogues in antitumor and antiviral drug discovery: A comprehensive review.

Purine-derived scaffolds remain important in anticancer and antiviral drug discovery because their electronic properties, hydrogen-bonding capacity, and conformational adaptability support interactions with kinases, polymerases, nucleotide-processing enzymes, and nucleic acids. This review critically examines three maj...

Manisha Nidhar, P. Alam, M. Alqarni et al. · European journal of medicina... · 0 citations

Jul 2026

Structure-Based identification of potent dengue virus RNA-dependent RNA polymerase inhibitors using integrated computational workflow

An integrated computational workflow was applied to identify potential inhibitors of dengue virus RNA-dependent RNA polymerase (RdRp) after screening of approximately 9,900 bioactive compounds through structure-based virtual screening and molecular docking, supporting these compounds as promising RdRp inhibitors.

T. M. Aljarba, A. Alam, Gopal Prasad Agrawal et al. · Molecular Simulation · 0 citations

Open access Jul 2026

Greenness, blueness, and whiteness profiles of HPTLC method for the simultaneous assay of tenofovir and emtricitabine in fixed-dose combination dosage forms

A sustainable reverse-phase HPTLC methodology for determining TEN and ECT concurrently in their fixed-dose combination (FDC) products is developed and verifies and suggested that the recommended method may be applied to precisely evaluate TEN and ECT in commercial formulations.

P. Alam, Faiyaz Shakeel, M. Alqarni et al. · BMC Chemistry · 0 citations